Impact of the growth hormone replacement on bone status in growth hormone deficient adults

Growth Hormone and IGF Research

Volumn 24, Issue 1, 2014, Pages 22-28

  Kuzma M ^a   Kuzmova Z ^a   Zelinkova Z ^a   Killinger, Z ^a   Vanuga P ^b   Lazurova I ^c   Tomkova S ^d   Payer, J ^a  

^a UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^b National Institute of Endocrinology and Diabetology   (Slovakia)

^c Med Faculty of Safarik University   (Slovakia)

^d Clinic of Burns and Reconstructive Surgery   (Slovakia)

Author keywords

Bone mineral density; Bone turnover marker; Growth hormone; IGF 1; Trabecular bone score

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; RECOMBINANT GROWTH HORMONE;

ADULT; ARTICLE; BONE DENSITY; BONE EXAMINATION; BONE REMODELING; BONE STRUCTURE; BONE TURNOVER; DRUG RESPONSE; FEMALE; FEMUR; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MICROMORPHOLOGY; ONSET AGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; TRABECULAR BONE SCORE;

BONE MINERAL DENSITY; BONE TURNOVER MARKER; GROWTH HORMONE; IGF-1; TRABECULAR BONE SCORE;

ADULT; AGE OF ONSET; BIOLOGICAL MARKERS; BONE DENSITY; BONE DEVELOPMENT; BONE REMODELING; CHILD; DIETARY SUPPLEMENTS; FEMALE; FOLLOW-UP STUDIES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; OSTEOPOROSIS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84893650617     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2013.12.001     Document Type: Article

References (61)

1. Killinger Z., Kuzma M., Sterancakova L., Payer J. Osteoarticular changes in acromegaly. Int. J. Endocrinol. 2012, 2012:839282.
2. Gillberg P., Mallmin H., Petren-Mallmin M., Ljunghall S., Nilsson A.G. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J. Clin. Endocrinol. Metab. 2002, 87(11):4900-4906.
3. Woods K.A., Camacho-Hubner C., Savage M.O., Clark A.J. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N. Engl. J. Med. 1996, 335(18):1363-1367.
4. Killinger Z., Payer J., Lazurova I., et al. Arthropathy in acromegaly. Rheum. Dis. Clin. North Am. 2010, 36(4):713-720.
5. van der Eerden B.C., Karperien M., Wit J.M. Systemic and local regulation of the growth plate. Endocr. Rev. 2003, 24(6):782-801.
6. Finkelstein J.S., Neer R.M., Biller B.M., Crawford J.D., Klibanski A. Osteopenia in men with a history of delayed puberty. N. Engl. J. Med. 1992, 326(9):600-604.
7. Rosen T., Wilhelmsen L., Landin-Wilhelmsen K., Lappas G., Bengtsson B.A. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur. J. Endocrinol. 1997, 137(3):240-245.
8. Brixen K., Nielsen H.K., Mosekilde L., Flyvbjerg A. A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J. Bone Miner. Res. 1990, 5(6):609-618.
9. Sartorio A., Ortolani S., Galbiati E., et al. Effects of 12-month GH treatment on bone metabolism and bone mineral density in adults with adult-onset GH deficiency. J. Endocrinol. Invest. 2001, 24(4):224-230.
10. Amato G., Carella C., Fazio S., et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J. Clin. Endocrinol. Metab. 1993, 77(6):1671-1676.
11. Degerblad M., Bengtsson B.A., Bramnert M., et al. Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12months of GH substitution therapy. Eur. J. Endocrinol. 1995, 133(2):180-188.
12. Arwert L.I., Roos J.C., Lips P., Twisk J.W., Manoliu R.A., Drent M.L. Effects of 10years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin. Endocrinol. (Oxf.) 2005, 63(3):310-316.
13. Biermasz N.R., Hamdy N.A., Janssen Y.J., Roelfsema F. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial. J. Clin. Endocrinol. Metab. 2001, 86(7):3079-3085.
14. Clanget C., Seck T., Hinke V., Wuster C., Ziegler R., Pfeilschifter J. Effects of 6years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults. Clin. Endocrinol. (Oxf.) 2001, 55(1):93-99.
15. Colson A., Brooke A.M., Walker D., et al. Growth hormone deficiency and replacement in patients with treated Cushing's Disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density. Horm. Res. 2006, 66(6):257-267.
16. Conway G.S., Szarras-Czapnik M., Racz K., et al. Treatment for 24months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. Eur. J. Endocrinol. 2009, 160(6):899-907.
17. Davidson P., Milne R., Chase D., Cooper C. Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. Clin. Endocrinol. (Oxf.) 2004, 60(1):92-98.
18. Elbornsson M., Gotherstrom G., Bosaeus I., Bengtsson B.A., Johannsson G., Svensson J. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur. J. Endocrinol. 2012, 166(5):787-795.
19. Elbornsson M., Gotherstrom G., Franco C., Bengtsson B.A., Johannsson G., Svensson J. Effects of 3-year GH replacement therapy on bone mineral density in younger and elderly adults with adult-onset GH deficiency. Eur. J. Endocrinol. 2012, 166(2):181-189.
20. Jorgensen A.P., Fougner K.J., Ueland T., et al. Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. Growth Horm. IGF Res. 2011, 21(2):69-75.
21. Rota F., Savanelli M.C., Tauchmanova L., et al. Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender. J. Endocrinol. Invest. 2008, 31(2):94-102.
22. Tritos N.A., Hamrahian A.H., King D., et al. Predictors Of The Effects Of 4 Years Of Growth Hormone Replacement On Bone Mineral Density In Patients With Adult-Onset Growth Hormone Deficiency - A Kims Database Analysis. Clin. Endocrinol. (Oxf.) 2013, 79(2):178-184.
23. Tritos N.A., Hamrahian A.H., King D., et al. A longer interval without GH replacement and female gender are associated with lower bone mineral density in adults with childhood-onset GH deficiency: a KIMS database analysis. Eur. J. Endocrinol. 2012, 167(3):343-351.
24. Arwert L.I., Deijen J.B., Muller M., Drent M.L. Long-term growth hormone treatment preserves GH-induced memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. Horm. Behav. 2005, 47(3):343-349.
25. Gotherstrom G., Bengtsson B.A., Bosaeus I., Johannsson G., Svensson J. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur. J. Endocrinol. 2007, 156(1):55-64.
26. Snyder P.J., Biller B.M., Zagar A., et al. Effect of growth hormone replacement on BMD in adult-onset growth hormone deficiency. J. Bone Miner. Res. 2007, 22(5):762-770.
27. Holmes S.J., Whitehouse R.W., Economou G., O'Halloran D.J., Adams J.E., Shalet S.M. Further increase in forearm cortical bone mineral content after discontinuation of growth hormone replacement. Clin. Endocrinol. (Oxf.) 1995, 42(1):3-7.
28. Janssen Y.J., Hamdy N.A., Frolich M., Roelfsema F. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency. J. Clin. Endocrinol. Metab. 1998, 83(6):2143-2148.
29. Johansson A.G., Engstrom B.E., Ljunghall S., Karlsson F.A., Burman P. Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. J. Clin. Endocrinol. Metab. 1999, 84(6):2002-2007.
30. Kann P., Piepkorn B., Schehler B., et al. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults. Clin. Endocrinol. (Oxf.) 1998, 48(5):561-568.
31. Longobardi S., Di R.F., Pivonello R., et al. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients. J. Endocrinol. Invest. 1999, 22(5):333-339.
32. Rahim A., Holmes S.J., Adams J.E., Shalet S.M. Long-term change in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy. Clin. Endocrinol. (Oxf.) 1998, 48(4):463-469.
33. Valimaki M.J., Salmela P.I., Salmi J., et al. Effects of 42months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. Eur. J. Endocrinol. 1999, 140(6):545-554.
34. Rosen T., Wiren L., Wilhelmsen L., Wiklund I., Bengtsson B.A. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin. Endocrinol. (Oxf.) 1994, 40(1):111-116.
35. Carter D.R., Bouxsein M.L., Marcus R. New approaches for interpreting projected bone densitometry data. J. Bone Miner. Res. 1992, 7(2):137-145.
36. Murray R.D., Adams J.E., Shalet S.M. A densitometric and morphometric analysis of the skeleton in adults with varying degrees of growth hormone deficiency. J. Clin. Endocrinol. Metab. 2006, 91(2):432-438.
37. Schweizer R., Martin D.D., Haase M., et al. Similar effects of long-term exogenous growth hormone (GH) on bone and muscle parameters: a pQCT study of GH-deficient and small-for-gestational-age (SGA) children. Bone 2007, 41(5):875-881.
38. Arends N.J., Boonstra V.H., Mulder P.G., et al. GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial. Clin. Endocrinol. (Oxf.) 2003, 59(6):779-787.
39. Bravenboer N., Holzmann P., de B.H., Blok G.J., Lips P. Histomorphometric analysis of bone mass and bone metabolism in growth hormone deficient adult men. Bone 1996, 18(6):551-557.
40. Bravenboer N., Holzmann P., de B.H., Roos J.C., van der Veen E.A., Lips P. The effect of growth hormone (GH) on histomorphometric indices of bone structure and bone turnover in GH-deficient men. J. Clin. Endocrinol. Metab. 1997, 82(6):1818-1822.
41. Bravenboer N., Holzmann P.J., ter Maaten J.C., Stuurman L.M., Roos J.C., Lips P. Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J. Bone Miner. Res. 2005, 20(10):1778-1784.
42. Evans B.A., Warner J.T., Elford C., et al. Morphological determinants of femoral strength in growth hormone-deficient transgenic growth-retarded (Tgr) rats. J. Bone Miner. Res. 2003, 18(7):1308-1316.
43. Kristensen E., Hallgrimsson B., Morck D.W., Boyd S.K. Microarchitecture, but not bone mechanical properties, is rescued with growth hormone treatment in a mouse model of growth hormone deficiency. Int. J. Endocrinol. 2012, 2012:294965.
44. Colson F., Picard A., Rabier B., Piperno M., Vignon E. Trabecular bone microarchitecture alteration in glucocorticoids treated women in clinical roin clinical routine?: A TBS evaluation. J. Bone Miner. Res. 2009, 24(Suppl. 1). (Ref Type: Generic).
45. Bréban S., Kolta S., Briot K., Paternotte S., Ghazi M., Fechtenbaum J., Dougados M., Roux C. Combination of bone mineral density and trabecular bone score for vertebral fracture prediction in secondary osteoporosis. J. Bone Miner. Res. 2010, 25. (Ref Type: Generic).
46. Leslie W.D., Aubry-Rozier B., Lamy O., Hans D. TBS (trabecular bone score) and diabetes-related fracture risk. J. Clin. Endocrinol. Metab. 2013, 98(2):602-609.
47. Molitch M.E., Clemmons D.R., Malozowski S., et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2006, 91(5):1621-1634.
48. Hans D., Barthe N., Boutroy S., Pothuaud L., Winzenrieth R., Krieg M.A. Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J. Clin. Densitom. 2011, 14(3):302-312.
49. Rosen T., Eden S., Larson G., Wilhelmsen L., Bengtsson B.A. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol. (Copenh) 1993, 129(3):195-200.
50. de B.H., Blok G.J., Voerman H.J., Phillips M., Schouten J.A. Serum lipid levels in growth hormone-deficient men. Metabolism 1994, 43(2):199-203.
51. Colao A., Di S.C., Pivonello R., et al. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J. Clin. Endocrinol. Metab. 1999, 84(6):1919-1924.
52. Bredella M.A., Lin E., Gerweck A.V., et al. Determinants of bone microarchitecture and mechanical properties in obese men. J. Clin. Endocrinol. Metab. 2012, 97(11):4115-4122.
53. Rosen T., Hansson T., Granhed H., Szucs J., Bengtsson B.A. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol. (Copenh) 1993, 129(3):201-206.
54. Holmes S.J., Economou G., Whitehouse R.W., Adams J.E., Shalet S.M. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J. Clin. Endocrinol. Metab. 1994, 78(3):669-674.
55. Koranyi J., Svensson J., Gotherstrom G., Sunnerhagen K.S., Bengtsson B., Johannsson G. Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: a comparative, prospective study. J. Clin. Endocrinol. Metab. 2001, 86(10):4693-4699.
56. Rossini A., Lanzi R., Losa M., et al. Predictors of bone responsiveness to growth hormone (GH) replacement in adult GH-deficient patients. Calcif. Tissue Int. 2011, 88(4):304-313.
57. Giustina A., Mazziotti G., Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 2008, 29(5):535-559.
58. ter Maaten J.C., de B.H., Kamp O., Stuurman L., van der Veen E.A. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J. Clin. Endocrinol. Metab. 1999, 84(7):2373-2380.
59. Johannsson G., Rosen T., Bosaeus I., Sjostrom L., Bengtsson B.A. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J. Clin. Endocrinol. Metab. 1996, 81(8):2865-2873.
60. Ohlsson C., Bengtsson B.A., Isaksson O.G., Andreassen T.T., Slootweg M.C. Growth hormone and bone. Endocr. Rev. 1998, 19(1):55-79.
61. de Paula F.J., Gois-Junior M.B., Aguiar-Oliveira M.H., et al. Consequences of lifetime isolated growth hormone (GH) deficiency and effects of short-term GH treatment on bone in adults with a mutation in the GHRH-receptor gene. Clin. Endocrinol. (Oxf.) 2009, 70(1):35-40.